Independent Wealth Network Inc. Has $599,000 Stock Holdings in Johnson & Johnson $JNJ

Independent Wealth Network Inc. trimmed its stake in Johnson & Johnson (NYSE:JNJ) by 5.9% in the second quarter, Holdings Channel reports. The firm owned 3,919 shares of the company’s stock after selling 245 shares during the quarter. Independent Wealth Network Inc.’s holdings in Johnson & Johnson were worth $599,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the stock. Highline Wealth Partners LLC grew its position in Johnson & Johnson by 51.8% during the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company’s stock valued at $42,000 after acquiring an additional 86 shares during the last quarter. Stone House Investment Management LLC purchased a new stake in shares of Johnson & Johnson during the 1st quarter worth approximately $47,000. 1248 Management LLC purchased a new position in Johnson & Johnson during the 1st quarter valued at $48,000. von Borstel & Associates Inc. bought a new stake in shares of Johnson & Johnson in the 1st quarter valued at about $49,000. Finally, Harvest Fund Management Co. Ltd acquired a new position in shares of Johnson & Johnson during the first quarter valued at about $52,000. Institutional investors own 69.55% of the company’s stock.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the transaction, the executive vice president directly owned 178,013 shares of the company’s stock, valued at $31,652,491.53. The trade was a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.16% of the stock is owned by insiders.

Johnson & Johnson Stock Performance

NYSE JNJ opened at $179.69 on Friday. The stock has a market cap of $432.75 billion, a PE ratio of 19.22, a P/E/G ratio of 2.29 and a beta of 0.40. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. The stock has a fifty day simple moving average of $174.41 and a 200-day simple moving average of $162.06. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $181.16.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, topping analysts’ consensus estimates of $2.68 by $0.09. The company had revenue of $23.74 billion for the quarter, compared to the consensus estimate of $22.85 billion. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.Johnson & Johnson’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same period in the previous year, the business earned $2.82 earnings per share. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Equities analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th were issued a $1.30 dividend. The ex-dividend date of this dividend was Tuesday, August 26th. This represents a $5.20 annualized dividend and a dividend yield of 2.9%. Johnson & Johnson’s payout ratio is 55.61%.

Analysts Set New Price Targets

A number of equities analysts recently commented on JNJ shares. Morgan Stanley lifted their price objective on Johnson & Johnson from $171.00 to $176.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 17th. The Goldman Sachs Group lifted their target price on Johnson & Johnson from $185.00 to $186.00 and gave the company a “buy” rating in a research note on Friday, September 19th. Royal Bank Of Canada upped their price target on Johnson & Johnson from $181.00 to $185.00 and gave the company an “outperform” rating in a report on Thursday, July 17th. UBS Group lifted their target price on Johnson & Johnson from $180.00 to $190.00 and gave the stock a “buy” rating in a research note on Thursday, July 17th. Finally, Bank of America increased their price objective on shares of Johnson & Johnson from $161.00 to $175.00 and gave the company a “neutral” rating in a research note on Thursday, July 17th. Two analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $181.40.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.